Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Polynovo ( (AU:PNV) ) has provided an announcement.
PolyNovo has conducted a comprehensive review of its corporate governance practices in alignment with the ASX Corporate Governance Council’s Principles and Recommendations. The company emphasizes ethical behavior, integrity, and compliance with the law to uphold its reputation and stakeholder trust. The governance framework includes a structured Board and committees, with a focus on diversity, performance evaluation, and ethical conduct, which are crucial for its operational integrity and industry positioning.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo is a company operating in the biotechnology industry, focusing on developing innovative medical solutions. The company is known for its advanced wound care products and is committed to maintaining high standards of corporate governance.
YTD Price Performance: -46.08%
Average Trading Volume: 2,086,632
Technical Sentiment Signal: Sell
Current Market Cap: A$759.9M
See more insights into PNV stock on TipRanks’ Stock Analysis page.